Understanding how trauma and blood loss increase the risk of sepsis
Mechanism of Trauma/Hemorrhagic Shock-Predisposed Sepsis
['FUNDING_R21'] · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · NIH-11099937
This study is looking at how a specific substance in the body, called 12(S)-HETE, might help us understand why people who have had severe injuries and blood loss are more likely to get serious infections like sepsis, so we can find better ways to protect those patients.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF PITTSBURGH AT PITTSBURGH (nih funded) |
| Locations | 1 site (PITTSBURGH, UNITED STATES) |
| Trial ID | NIH-11099937 on ClinicalTrials.gov |
What this research studies
This research investigates the mechanisms by which severe trauma and hemorrhagic shock can lead to an increased risk of sepsis, a life-threatening infection. The study focuses on a specific metabolite, 12(S)-HETE, and its role in regulating inflammation and immune response in patients who have experienced trauma. By examining how this metabolite affects the expression of the ALOX15 enzyme, the research aims to identify potential targets for preventing sepsis in at-risk patients. The approach includes analyzing blood samples from trauma patients to understand the relationship between 12(S)-HETE levels and infection susceptibility.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have experienced severe trauma or hemorrhagic shock and are at risk of developing sepsis.
Not a fit: Patients who have not experienced severe trauma or hemorrhagic shock may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for preventing sepsis in patients who have suffered severe trauma.
How similar studies have performed: Previous studies have shown that understanding the role of specific metabolites in trauma patients can provide valuable insights, suggesting that this research could build on established findings.
Where this research is happening
PITTSBURGH, UNITED STATES
- UNIVERSITY OF PITTSBURGH AT PITTSBURGH — PITTSBURGH, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: FAN, JIE — UNIVERSITY OF PITTSBURGH AT PITTSBURGH
- Study coordinator: FAN, JIE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.